UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2007

BioCryst Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Delaware	000-23186	62-1413174
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2190 Parkway Lake Drive, Birmingl	ham, Alabama	35244
(Address of Principal Executive Offices) (Zip Code)		(Zip Code)
	s telephone number, including area code: (2)	<u></u>
(Former	name or former address if changed since ia	st report.)
Check the appropriate box below if the Form under any of the following provisions:	8-K filing is intended to simultaneously sa	tisfy the filing obligation of the registrant
o Written communications pursuant to Rule	425 under the Securities Act (17 CFR 230.4	25)
o Soliciting material pursuant to Rule 14a-12	under the Exchange Act (17 CFR 240.14a-	12)
o Pre-commencement communications pursu	ant to Rule 14d-2(b) under the Exchange A	ct (17 CFR 240.14d-2(b))
o Pre-commencement communications pursu	ant to Rule 13e-4(c) under the Exchange A	ct (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 11, 2007, Randall B. Riggs, the Senior Vice President, Business Development of BioCryst Pharmaceuticals, Inc. (the "Company"), tendered his resignation from employment with the Company, effective October 12, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 17, 2007	BioCryst Pharmaceuticals, Inc.		
	By:	/s/ Michael A. Darwin	
		Michael A. Darwin	
		Vice President Finance	